reason report
bottom line initi coverag
inc outperform rate price target pt
advm lead asset phase trial one-tim
intravitr therapi treatment wet age-rel macular degener
wet despit safe effect standard care anti-vegf
treatment eylea op lucenti roch genentech
nv nr avastin roch genentech nr high inject burden
remain unmet need mani patient requir frequent inject
everi week posit reduc treatment
burden recent demonstr posit data phase trial
patient effect manag diseas without need anti-
administr profil lead asset upsid option
includ model use beyond wet see attract
risk/reward profil share current valuat
intravitr rout administr offer distinct
advantag wet treatment approach
clinic landscap wet quit competit
intravitr rout allow straightforward integr exist physician
mp requir surgic procedur administr lead
candid potenti make therapi less attract patient
physician
present larg opportun wet-amd estim
total anti-vegf market wet current believ
could see peak sale model
probabl success impli probability-weight peak
sale reflect still early-to-mid-stag natur program
larg expans opportun diabet retinopathi dr
patient dr respons anti-vegf treatment
mani benefit anti-vegf therapi requir substanti inject
burden see ration expans indic
although ascrib explicit valu program
model plan file ind dr
begin enrol patient trail
financi glanc cash equival
compani rais addit net proce
mid-februari equiti offer expect fund oper
multipl clinic catalyst wet
well earli data patient diabet retinopathi
gener per share share outstand
year price history/av daili volume mil
compani inform svb leerink llc research
revenu million ep
pleas refer page import disclosur price chart analyst certif
rate outperform lead asset uniqu valu proposit
treatment wet administ one-tim intravitr inject
success clinic believ would hold broad appeal wet patient
could integr current ophthalmolog practic estim
could approv see probability-unadjust peak sale
addit clinic disclosur on-going optic trial near-term valu driver
clinical-stag compani develop
intravitr gene therapi treatment wet lead asset aav-
base gene therapi intend treat wet one-tim intravitr inject advm-
util proprietari vector induc express aflibercept eylea
anti-vegf antibodi within retin cell creat direct
evolut except tropism retin cell vector induc strong
gene express cell across retina fovea intravitr inject non-
human primat nhp model dalkara et al scienc translat
demonstr long-term aflibercept express month singl inject
grishanin et al esgct strong proof-of-concept phase data conveni
intravitr mode administr easili integr exist practic pattern
believ stage set safeti efficaci data could posit
wet therapi broad market appeal
despit effect standard care treatment high inject burden remain unmet
need wet standard-of-car anti-vegf treatment safe highli
effect treat wet mani patient requir inject frequent everi
week manag diseas one-tim therapi posit reduc
treatment burden could improv outcom patient troubl adher
frequent anti-vegf inject base medacorp kol feedback estim
wet patient maintain short disease-fre interv requir frequent anti-vegf
inject repres larg segment patient like benefit gene
interim phase clinic data demonstr activ wet clear
dose respons phase clinic trial on-going interim data
present plan dose cohort patient treat cohort
effect manag diseas without need rescu anti-vegf inject
patient treat lower dose cohort gone without need rescu
inject median follow week data suggest favor efficaci
profil dose vg/ey help establish better sens
minim effect dose gene therapi given partial respons
intravitr gene therapi neatli fit current practic pattern gene therapi
deliv intravitr inject current standard-of-car anti-vegf therapi
clinic landscap wet quit competit sever longer-act
treatment develop intravitr rout administr provid distinct
advantag compet approach treat wet gene
therapi implant port deliveri system requir surgic procedur
administr could make therapi less attract patient requir
substanti chang physician practic structur comparison widespread physician
adopt would requir substanti chang retin practic advm-
administ similar manner standard care anti-vegf inject
pipelin advm lead gene therapi program treatment wet
current phase clinic studi studi diabet retinopathi expect initi
addit compani preclin stage develop investig gene
therapi treatment hereditari angioedema exhibit potenti life-
threaten condit character recurr sever swell attack involv throat
face extrem intens abdomin pain compani expect provid
updat program later year
runway expect fund oper approxim
cash cash equival short-term invest compani rais addit
net proce mid-februari equiti offer expect cash
cash equival short-term invest fund oper multipl
potenti value-gener catalyst wet diabet retinopathi
wet age-rel macular degener wet one common caus
vision loss unit state wet caus exud fluid
overprolifer blood vessel eye lead thicken central retina
format scar tissu loss vision estim million adult current
affect wet unit state alon sinc wet commonli occur
adult age number wet patient project grow
popul age pennington et al vi
anti-vegf therapi standard-of-car wet treatment vascular endotheli
growth factor vegf key signal peptid promot growth blood vessel
angiogenesi eye standard-of-car anti-vegf antibodi eylea lucenti
avastin sequest vegf block format new blood vessel respons loss
vision wet patient initi anti-vegf treatment usual begin
intravitr inject everi month first month therapi induct follow
gradual extens treatment interv largest window patient remain
symptom-fre mainten treat-and-extend patient median time week
inject mani patient extend treatment interv everi
week howev mani patient maintain short disease-fre interv requir
retreat everi week order maintain retin integr estim
wet patient need anti-vegf inject everi week maintain vision
accord convers medacorp kol complianc frequent inject
difficult mani older patient frequent injector costli payer provid
incent frequent injector patient payer consid gene therapi
anti-vegf market estim greater combin
world-wide sale eylea lucenti reach base medacorp
physician feedback review retin diseas epidemiolog estim
anti-vegf sale wet suggest wet market achiev
sale given age popul unit state europ expect
wet market continu expand time progress
highli competit environ like limit price opportun wet
gene therapi believ potenti conveni advantag one-tim intravitr wet
treatment would see broad appeal among frequent injector patient potenti cost
save vs frequent chronic anti-vegf inject could incentiv payor encourag
treatment approv earlier work wet market see
initi found price point would pariti three
year standard-of-car anti-vegf therapi would attract payer though
gene therapi clinic data demonstr longer durat benefit could potenti
command higher price note longer-last vs current standard care
therapi clinic develop could crowd competit wet
market dont expect price dynam chang forese futur
though sizabl market still provid substanti opportun gene therapi
across coverag univers commonli develop rare diseas often
pediatr popul market price contrast approxim
patient diagnos wet everi year unit state american macular
degener foundat price like appropri line
multi-year cost standard care anti-vegf therapi see see
substanti pool sever wet patient among safe effect intravitr
one-tim therapi could see meaning adopt time total anti-vegf market
wet current believ could see peak sale
approxim model probabl success impli
probability-weight peak sale exhibit
arriv price target share base dcf methodolog
model base develop wet singl indic
price target sensit chang probabl success program
price assumpt exhibit given strong preclin data date
pristin safeti efficaci profil aflibercept wet assum
probabl success indic also plan develop diabet
retinopathi current incorpor indic model recogn
continu progress clinic program would repres upsid current
exhibit sensit analysi
long-term efficaci safeti profil critic commerci
adopt wet anti-vegf therapi well-toler low rate
complic believ meet high safeti toler
profil drive commerci uptak convers medacorp kol regularli
treat wet patient anti-vegf therapi indic year patient follow-up
clean safeti profil would need comfort recommend gene
therapi patient sever diseas high inject burden
exhibit market model wet
util novel vector deliv codon-optim aflibercept
code sequenc encod code sequenc produc aflibercept
ident vegf trap fusion protein eylea aflibercept consist extracellular vegf-
bind domain vegf receptor vegf receptor fuse fc region human
immunoglobulin exhibit fusion protein proven safe effect
treat wet clinic trial extens real-world use reason
expect long-term express aflibercept similar on-target
design enhanc express protein product includ human
cytomegaloviru cmv immediate-earli enhanc promot adenoviru tripartit
leader sequenc tpl major late promot enhanc element emlp grishanin et
al molecular therapi exhibit construct show good express
aflibercept retin cell non-human primat nhp model produc therapeut
concentr aflibercept retin humor vitreou humor grishanin et al esgct
exhibit aflibercept sequest vegf ligand receptor
appear induc strong retin gene transduct intravitr
inject uniqu properti among aav vector capsid produc
direct evolut optim intravitr administr compar
base sequenc contain amino acid insert loop iv
structur thought increas tropism toward retin cell exhibit red
portion natur occur aav serotyp poor transduct outer retina
administ vitreou amino sequenc disrupt loop arginin
residu involv bind primari cell receptor heparan sulfat
facilit higher gene express inner nuclear layer inner plexiform layer
ganglion cell layer retina compar
previou gener capsid isol increas retin transduct hickey et
preclin data demonstr durabl express aflibercept least
month longest patient follow-up clinic trial reach week post-
administr preclin data nhp anim model show sustain
aflibercept express least month aflibercept express maintain
vitreou aqueou humor studi though lower level
aqueou humor exhibit rational dose select clinic trial part base
studi evalu steady-st level aflibercept nhp eye produc
vs bolu inject aflibercept fifty-six day administr
nhp treat demonstr steady-st aflibercept concentr
ug/g retina exhibit similar level seen week bolu inject
aflibercept sinc even frequent injector manag wet inject everi
week vg/ey dose good rational effect dose
long-term treatment wet patient though initi clinic studi found patient
robust respons lower dose vg/ey
exhibit aflibercept express aqueou vitreou humor
phase optic trial on-going posit interim result
first two dose cohort present open-label optic trial exhibit
current evalu two separ dose treatment wet
trial origin plan dose escal would assess dose
 vg/ey three separ cohort interim analysi determin
robust respons cohort compani dose vg/ey
cohort instead vg/ey date interim result cohort cohort
present two addit cohort evalu ident dose level
cohort dose vg/ey cohort dose
initi interim result phase optic trial shown clear activ advm-
wet patient cohort dose w/ vg/ey maintain vision
without need rescu inject demonstr improv retin anatomi
median follow-up week administr cohort patient
requir frequent anti-vegf inject baselin averag anti-vegf
treatment month prior enrol optic approxim one inject everi
week administr patient requir rescu
inject median follow-up week exhibit maintain vision
averag one letter decreas best correct visual acuiti bcva baselin
dose respons cohort provid evid drug activ four
patient dose lower concentr requir rescu
inject median week follow-up exhibit patient also
frequent injector baselin requir number anti-vegf inject
cohort prior enrol trial though two patient requir rescu inject
clear dose-respons cohort reassur provid compani
better sens minim effect dose support develop
manag state within therapeut dose rang need
conduct dose escal base data
optic patient substanti improv retin anatomi patient cohort
experienc decreas central subfield thick baselin measur
optic coher tomographi oct object measur retin physiolog
suggest improv underli wet patholog exhibit investig report
patient cohort even saw decreas bcva maintain dri retina
fluid build-up seen oct trigger criteria rescu anti-vegf inject
lower-dos cohort patient requir rescu inject howev cohort
whole see central subfield thick baselin exhibit
prior clinic readout cohort spoke medacorp kol
extens experi treat wet opinion decreas central retin
thick would display clear activ decreas
would absolut homerun cohort show decreas central subfield
thick meet kol bar clear drug activ unknown
patient stabl anti-vegf therapi year would show decreas
subretin thick patient recruit earlier diseas cours could see greater
exhibit interim optic trial result cohort
exhibit cohort mean bcva mean cst week
grade-inflamm commonli occur advers event ae clinic trial
though well manag topic steroid eyedrop patient cohort
cohort treat prophylact corticosteroid regimen though
inflamm emerg common ae administr exhibit
howev inflamm assess low-grad well control steroid
eyedrop cohort patient appear maintain use steroid eyedrop week
cohort vg/eyenumb follow weeksinjection-fre rescu chang bcva etdr bcva chang etdr chang cst crt chang adverum inc
treatment rais investor concern chronic use steroid patient
howev wet kol compani event suggest steroid eyedrop commonli
use surgic ophthalmolog procedur would expect inflamm
resolv time go forward longer use oral steroid cohort
plan begin treat patient prophylact steroid eye drop regimen follow
treatment as-need beyond period otherwis protocol use cohort
 similar earlier cohort time primari endpoint trial remain
week expect see data cohort manag guid
complet patient dose cohort screen current underway
exhibit low-grad inflamm cohort
diabet retinopathi dr repres potenti larg expans opportun
ind file expect mani diabet retinopathi patient benefit anti-
vegf therapi penetr anti-vegf therapi widespread dr wet
dr retinopathi patient often requir frequent dose anti-vegf treatment
wet patient patient dr respons anti-vegf treatment
may introduc larger degre clinic risk wet although could
address limit studi known anti-vegf respond
develop addit proprietari vector provid long-term pipelin
opportun explicitli valu model note could develop
addit novel capsid direct evolut platform techniqu abl
develop uniqu tropism retin cell administ
intravitr inject exampl esgct identifi loop
substitut variant novel aav capsid variant deriv direct
evolut screen via intravitr inject nhp eye exhibit
exhibit demonstr widespread express nhp eye
manufactur strategi employ in-hous capac clinic develop
potenti scale contract manufactur organ cmo
commerci januari move new squar foot corpor
headquart includ laboratori space manufactur process capabl
manag indic current manufactur capac in-hous
plan move system soon sourc competitor confer januari
compani util insect cell-bas system highli scalabl
could easili transfer manufactur practic gmp capabl
taken whole see well-posit manufactur suppli current
plan clinic trial scale via contract develop manufactur organ
cdmo compani approach commerci
addit clinic preclin data present
previous schedul present oral present optic studi
associ research vision ophthalmolog arvo meet may
howev arvo confer recent cancel remain unclear
data present time expect first readout
cohort format similarli earlier cohort show primari secondari
endpoint includ bcva chang central subfield thick cst safeti
addit look toward submiss ind diabet retinopathi
collabor provid addit option agreement cover
total target includ pre-specified addit target includ
treatment juvenil x-link retinoschisi development commerci
mileston avail individu target total includ everi
potenti mileston right co-fund would respons
develop cost elig low-singl digit low-doubl digit royalti
co-fund though program could provid addit option
develop program earli stage term deal set expir may
current contempl program model without
clariti develop
leon patterson emba chief execut offic director leon
patterson join adverum june chief financi offic serv chief
execut offic sinc may ms patterson year experi
biotechnolog industri previous serv cfo diadexu inc prior ms patterson
vice presid chief financi offic inc held
posit numer biopharma compani throughout career ms patterson
earn busi administr account chapman univers
execut st mari colleg
thoma leung chief offic thoma leung join adverum april
mr leung fifteen year busi experi healthcar privat equiti
invest bank mr leung recent vice presid busi oper
counsyl hold leadership role financ strategi bill oper sale oper
mr leung earn harvard busi school biomed
engin econom yale
aaron osborn mbb chief medic offic aaron osborn mbb join adverum
april dr osborn twelv year experi biopharmaceut
industri togeth five year clinic practic british nation health servic
nh ophthalmologist dr osborn bring previou experi genentech
serv princip medic director product develop global
develop leader faricimab guid design execut phase ii phase
studi wet age-rel macular degener diabet macular edema dme
respect dr osborn train ophthalmolog queen medic centr nottingham
earn bachelor medicin bachelor surgeri mbb degre univers
price target base discount cash flow
methodolog includ compani net cash balanc project potenti revenu
wet risk-adjust basi explicitli model expens
forecast result cash flow assign termin growth rate
discount rate consist clinical-stag pre-revenu compani coverag
risk view outlook valuat includ setback
clinic develop threat unmodel competit entrant potenti challeng
manufactur current advanc sole clinic asset
result neg impact safeti toler profil impli
lower probabl success could outsiz effect estim addit
major chang reimburs coverag wet cur gene therapi
unit state europ could impact estim
cash equival market secur
cash equival
prepaid expens current asset
oper leas right use asset
properti equip net
deposit long-term asset
accru expens current liabil
defer rent net current portion
total liabil
defer revenu net current portion
leas liabil net current portion
accumul comprehens incom loss
total liabil stockhold equiti deficit
compani report svb leerink equiti research estim
chang
oper
depreci amort
amort premium market secur
amort oper leas right-of-us asset
accret interest bpi
non-cash research develop expens
impair intang asset
chang oper asset liabil
prepaid expens current asset
accru expens current liabil
net invest
purchas market secur
sale market secur
matur market secur
purchas properti equip
acquir busi acquisit
flow financ
proce offer common stock net issuanc cost
proce issuanc common stock pursuant option
tax paid relat net share settlement restrict stock unit
proce employe stock purchas plan
proce financ arrang
repay loan
effect foreign currenc exchang rate cash cash
issuanc common stock exchang stock option busi acquisit
fix asset account payabl accru expens current liabil
cash equival begin period
cash equival end period
unpaid defer offer cost account payabl accru expens
compani report svb leerink equiti research estim
research develop
gener administr
sale market
net loss incom tax benefit
net loss attribut common stockhold
compani report svb leerink equiti research estim
brand
type event
event trial detail
expect
present new clinic data optic trial
may arvo
submit ind diabet retinopathi
present clinic data cohort
begin enrol patient plan phase
clinic trial diabet retinopathi
svb leerink llc equiti research compani file
